pSivida Corp. (PSDV)

2.22
0.06 2.42
NASDAQ : Health Technology
Prev Close 2.27
Open 2.26
Day Low/High 2.13 / 2.27
52 Wk Low/High 0.93 / 2.88
Volume 300.85K
Avg Volume 358.80K
Exchange NASDAQ
Shares Outstanding 45.16M
Market Cap 51.94M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
PSivida Corp. Announces Interim Data From Investigator-Sponsored Uveitis Study

PSivida Corp. Announces Interim Data From Investigator-Sponsored Uveitis Study

pSivida Corp. (NASDAQ:PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for the treatment of back-of-the-eye diseases, today announced interim data from an ...

PSivida Corp. Announces Initiation Of Phase III Clinical Trial In Posterior Uveitis

PSivida Corp. Announces Initiation Of Phase III Clinical Trial In Posterior Uveitis

pSivida Corp. (NASDAQ:PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, today announced that it has initiated the first of two...

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look poised to trade higher from current levels.

PSivida Corp. Announces UK’s NICE Says Yes To ILUVIEN® In Some Patients With Diabetic Macular Edema In New Draft Guidance

PSivida Corp. Announces UK’s NICE Says Yes To ILUVIEN® In Some Patients With Diabetic Macular Edema In New Draft Guidance

pSivida Corp. (NASDAQ: PSDV - News), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that the United Kingdom’s National...

4 Stocks Under $10 Making Big Moves

4 Stocks Under $10 Making Big Moves

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

5 Stocks Under $10 Set to Surge

5 Stocks Under $10 Set to Surge

These under-$10 stocks look poised to trade higher from current levels.

PSivida Reports Updates On ILUVIEN® For Planned Resubmission To FDA And European Launch

PSivida Reports Updates On ILUVIEN® For Planned Resubmission To FDA And European Launch

pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a specialty pharmaceutical company that is a leader in the development of sustained release ophthalmic drug treatments, today announced that its licensee Alimera Sciences, Inc.

PSivida VP Of Research To Discuss Company’s Protein And Antibody Sustained Delivery System At 5th Ocular Diseases And Drug Development Conference

PSivida VP Of Research To Discuss Company’s Protein And Antibody Sustained Delivery System At 5th Ocular Diseases And Drug Development Conference

pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a specialty pharmaceutical company that is a leader in the development of sustained release ophthalmic drug treatments, today announced that the Company’s Vice President of ...

PSivida Corp. Reports Second Quarter Fiscal Year 2013 Results

PSivida Corp. Reports Second Quarter Fiscal Year 2013 Results

pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its second quarter ended ...

PSivida CEO To Present At 15th Annual BioCEO & Investor Conference February 12

PSivida CEO To Present At 15th Annual BioCEO & Investor Conference February 12

pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), an emerging specialty pharmaceutical company and leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its...

PSivida Corp. Announces Second Quarter 2013 Financial Results Release Date And Conference Call Information

PSivida Corp. Announces Second Quarter 2013 Financial Results Release Date And Conference Call Information

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its financial results for the second quarter of...

Psivida Corp. Announces Final Published Guidance From U.K.’s Nice And Pursuit Of Patient Access Scheme For Iluvien® For DME

Psivida Corp. Announces Final Published Guidance From U.K.’s Nice And Pursuit Of Patient Access Scheme For Iluvien® For DME

pSivida Corp. (NASDAQ: PSDV - News), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that the United Kingdom’s National...

PSivida Corp. Announces Spain Grants ILUVIEN® Marketing Approval For Chronic Diabetic Macular Edema

PSivida Corp. Announces Spain Grants ILUVIEN® Marketing Approval For Chronic Diabetic Macular Edema

pSivida Corp. (NASDAQ: PSDV - News), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that the Spanish Agency of Drugs and Medical...

PSivida Corp. Reports Patient Access Scheme Being Developed By Alimera To Address Cost Concerns Following Negative Final Draft Guidance By U.K.’s NICE For ILUVIEN® For DME

PSivida Corp. Reports Patient Access Scheme Being Developed By Alimera To Address Cost Concerns Following Negative Final Draft Guidance By U.K.’s NICE For ILUVIEN® For DME

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that the United Kingdom’s National Institute...

PSivida Corp. Reports First Quarter Fiscal Year 2013 Results

PSivida Corp. Reports First Quarter Fiscal Year 2013 Results

pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its first quarter ended ...

PSivida Corp Announces First Quarter 2013 Financial Results Release Date And Conference Call Information

PSivida Corp Announces First Quarter 2013 Financial Results Release Date And Conference Call Information

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its financial results for the first quarter of...

PSivida CEO To Discuss Sustained Delivery And Nanotechnology In Ophthalmology At Upcoming Massachusetts Biotechnology Council Meeting

PSivida CEO To Discuss Sustained Delivery And Nanotechnology In Ophthalmology At Upcoming Massachusetts Biotechnology Council Meeting

pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its President and CEO, Dr.

PSivida Corp. Reports Fourth Quarter And Fiscal Year 2012 Results

PSivida Corp. Reports Fourth Quarter And Fiscal Year 2012 Results

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its fourth quarter and fiscal...

PSivida Corp. Announces Fourth Quarter And Fiscal Year 2012 Financial Results Release Date And Conference Call Information

PSivida Corp. Announces Fourth Quarter And Fiscal Year 2012 Financial Results Release Date And Conference Call Information

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its financial results for the fourth quarter and...

PSivida Corp. Reports U.K. National Institute For Health And Clinical Evidence Accepts ILUVIEN® Subgroup Data For Review

PSivida Corp. Reports U.K. National Institute For Health And Clinical Evidence Accepts ILUVIEN® Subgroup Data For Review

pSivida Corp. (NASDAQ: PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that the United Kingdom’s National Institute for...

PSivida CEO To Discuss Sustained Delivery And Nanotechnology In Ophthalmology At Drug Delivery Technologies & Formulation Conference In Switzerland

PSivida CEO To Discuss Sustained Delivery And Nanotechnology In Ophthalmology At Drug Delivery Technologies & Formulation Conference In Switzerland

pSivida Corp. (NASDAQ: PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that Dr.

PSivida To Present At Two Investment Conferences In September

PSivida To Present At Two Investment Conferences In September

pSivida Corp. (NASDAQ: PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that it will present at two upcoming investor...

PSivida Corp. Announces Closing Of $5.36 Million Registered Direct Financing

PSivida Corp. Announces Closing Of $5.36 Million Registered Direct Financing

pSivida Corp. (NASDAQ: PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that it closed the previously-announced securities...

PSivida Corp. Announces $5.36 Million Registered Direct Financing

PSivida Corp. Announces $5.36 Million Registered Direct Financing

pSivida Corp. (NASDAQ: PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that it has entered into a securities purchase...

PSivida Corp. Reports Alimera’s Intention To Resubmit Application To FDA For ILUVIEN® In DME Using Data From Completed Trials

PSivida Corp. Reports Alimera’s Intention To Resubmit Application To FDA For ILUVIEN® In DME Using Data From Completed Trials

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today reported that its licensee Alimera Sciences, Inc.

PSivida Corp. Announces Tech Evaluation Agreement For Tethadur™ Protein/Antibody Delivery System With Leading Biopharmaceutical Company

PSivida Corp. Announces Tech Evaluation Agreement For Tethadur™ Protein/Antibody Delivery System With Leading Biopharmaceutical Company

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that it has signed a funded technology evaluation...

PSivida Corp. Announces Germany Grants ILUVIEN® Marketing Authorization For The Treatment Of Chronic Diabetic Macular Edema

PSivida Corp. Announces Germany Grants ILUVIEN® Marketing Authorization For The Treatment Of Chronic Diabetic Macular Edema

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the Federal Ministry of Health of Germany...

4 Stocks Under $10 Making Big Moves

4 Stocks Under $10 Making Big Moves

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

PSivida Corp. Receives FDA Clearance For Pivotal Trials For Injectable Sustained-Release Micro-Insert To Treat Uveitis

PSivida Corp. Receives FDA Clearance For Pivotal Trials For Injectable Sustained-Release Micro-Insert To Treat Uveitis

pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that the U.

PSivida Corp. Announces France Grants ILUVIEN® Marketing Authorization For The Treatment Of Chronic Diabetic Macular Edema

PSivida Corp. Announces France Grants ILUVIEN® Marketing Authorization For The Treatment Of Chronic Diabetic Macular Edema

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the National Security Agency of Medicines and Health...